Stocks to sell

At long last, after taking a beating all year long SoFi Technologies (NASDAQ:SOFI) stock had a good day. On Nov. 1 share shot higher after SoFi released its third-quarter 2022 financial results. Yet, those gains were quickly coughed up as SOFI stock retreated over the next couple of days. Investors must ask themselves: Why did this happen, and
0 Comments
For years, investing in growth stocks was the key to building an incredible long-term portfolio. Investing in such stocks resulted in oversized returns, which enabled investors to build a robust portfolio. However, given the wild market gyrations, growth stocks have dipped to multi-year lows. Though this may seem like an excellent opportunity, it’s more prudent
0 Comments
Although an uncomfortable subject based on financial sensitivities, the topic of Nasdaq stocks to avoid cannot be avoided much longer. To be clear, it’s not so much about the companies specifically. Rather, with the Federal Reserve committed to its hawkish monetary policy, borrowing costs will rise. With that, the incentive for expansion-driven protocols will likely
0 Comments
Suffice it to say, microprocessor manufacturer Intel (NASDAQ:INTC) stock has disappointed its investors for the majority of 2022. However, financial traders went into a feeding frenzy with INTC stock after the company reported its quarterly earnings. They apparently ignored a number of issues that Intel is still facing. Furthermore, one analyst reaffirmed a $20 price target
0 Comments
If there’s one thing we learn in a market crash, it’s that no company is too big to fail. The financial crisis of 2008 had plenty of memorable examples, from Lehman Brothers to Circuit City. But one other legacy of 2008 is that too many investors fixate on “bull markets” and “bear markets” in stocks… Even
0 Comments
Based in New York, Mind Medicine (NASDAQ:MNMD) is a psychedelic-medicine developer that’s sometimes informally known as MindMed. Before investing in this company, it’s important to know that MNMD stock was previously out of compliance with the Nasdaq exchange’s listing requirements. This is a problem that could happen again in the near future. Moreover, Mind Medicine is
0 Comments
Before you consider taking a long position in Salesforce (NYSE:CRM)stock, be sure to get the full picture. The headlines might bombard you with news of an activist investor taking a stake in CRM stock. It’s fine to learn about this development, but Salesforce’s forward financial guidance should be top-of-mind. All things considered, it’s difficult to offer
0 Comments